ESR1 and benign neoplasm: The recurrence-free survival of ER/PR negative and lymph node positive patients classified according to TMEPAI expression, at median cut-off, indicated that high TMEPAI expression correlates with shorter survival with a hazard ratio (HR) of 2.69 and a log-rank P value of 0.002 (Fig.1A) and therefore carries an unfavorable prognostic significance in ER negative and lymph node positive breast cancer patients.